Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2014. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility under the GlaxoSmithKline Deferred Investment Award Programme.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction notifications.
Material Changes
On January 13, 2014, the Administrators of the Deferred Investment Award Programme notified the Company of increases in notional interests in Ordinary Shares for specific individuals. These increases resulted from the re-investment of the dividend paid to shareholders on January 9, 2014. The transaction price was 1611.25 pence per Share.
- Mr J Ford: 46.685 shares
- Mr S A Hussain: 161.366 shares
- Ms E Walmsley: 656.149 shares
- Mrs V A Whyte: 174.027 shares
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a compliance notification pursuant to Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Checklist
- Verify the dividend payment date of January 9, 2014, and the corresponding re-investment price of 1611.25 pence.
- Confirm the updated notional share holdings for the named directors and managers.
- Review the full terms of the GlaxoSmithKline Deferred Investment Award Programme for context on these transactions.